Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 4, 2009

Otsuka’s Vasopressin Agonist Approved in Europe for Hyponatremia

  • The European Commission sanctioned Otsuka Pharmaceutical’ s Samsca™ for the treatment of hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion in adults. This once-daily oral V2-vasopressin receptor antagonist is reportedly the first such drug available in Europe.

    Samsca is designed to promote aquaresis, i.e., the excretion of electrolyte-free water rather than diuresis, in which both sodium and water are released. 

    European approval follows FDA clearance of Samsca in May as the only oral selective vasopressin antagonist for the treatment of patients with clinically significant hypervolemic and euvolemic hyponatremia including patients with heart failure, cirrhosis, and SIADH. This is marked by serum sodium of less than 125 mEq/L or lower hyponatremia that is symptomatic and has resisted correction with fluid restriction.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »